Effect of acute glucose antagonism on hypophyseal hormones and concentrations of insulin-like growth factor (IGF)-I and IGF-binding proteins in serum, anterior pituitary, and hypothalamus of ewes.
The objectives of this study were to determine whether 2-deoxy-D-glucose (2DG), a metabolic inhibitor of glucose, 1) differentially affected release of LH, growth hormone (GH) and prolactin (PRL); 2) decreased anterior pituitary response to GnRH; and 3) altered concentrations of insulin-like growth factor I (IGF-I) and intensity of 125I-IGF-I binding to proteins (IGFBPs) in serum, anterior pituitary (AP), and hypothalamus (preoptic are [POA], medial basal hypothalamus [MBH], and stalk median eminence [SME]). In trial 1, mature, ovariectomized, crossbred ewes were treated with a single s.c. injection of either saline (n = 5) or 2DG (n = 5; 0.1 g/kg BW). Administration of 2DG suppressed (p < 0.05) concentrations of LH but did not affect (p > 0.05) serum concentrations of GH or PRL. In trial 2, ovariectomized ewes received injections of saline or 2DG, and each group was subdivided to receive either saline or GnRH analog (5 micrograms; Des-Gly10-[D-Ala6]) 2 h later. Administration of 2DG suppressed (p < 0.05) serum concentrations of LH before administration of GnRH; however, release of LH in response to exogenous GnRH was greater (p < 0.05) in ewes that received 2DG. Treatment with 2DG did not affect (p > 0.05) concentrations of FSH before or after administration of GnRH. In trial 3, 10 ovariectomized ewes were slaughtered 2 h after treatment with saline (n = 5) or 2DG (n = 5). Serum and tissues collected at slaughter (AP, MBH, SME, and POA) were analyzed for concentrations of IGF-I by RIA and intensity of 125I-IGF-I binding to proteins by ligand blotting.(ABSTRACT TRUNCATED AT 250 WORDS)
Funston
R N
RN
Department of Animal Science, University of Wyoming, Laramie 82071, USA.
Roberts
A J
AJ
Hixon
D L
DL
Hallford
D M
DM
Sanson
D W
DW
Moss
G E
GE
D000818:Animals; D002352:Carrier Proteins / Q000097:blood / Q000378:metabolism*; D003847:Deoxyglucose / Q000494:pharmacology; D005260:Female; D005947:Glucose / Q000037:antagonists & inhibitors*; D007987:Gonadotropin-Releasing Hormone / Q000494:pharmacology; D013006:Growth Hormone / Q000378:metabolism; D007031:Hypothalamus / Q000378:metabolism*; D018969:Insulin-Like Growth Factor Binding Proteins; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D007986:Luteinizing Hormone / Q000378:metabolism; D010052:Ovariectomy; D010903:Pituitary Gland, Anterior / Q000187:drug effects / Q000378:metabolism*; D010907:Pituitary Hormones / Q000378:metabolism*; D011301:Preoptic Area / Q000378:metabolism; D011388:Prolactin / Q000378:metabolism; D012756:Sheep
D002352:Carrier Proteins; D018969:Insulin-Like Growth Factor Binding Proteins; D010907:Pituitary Hormones; D007987:Gonadotropin-Releasing Hormone; D007334:Insulin-Like Growth Factor I; D011388:Prolactin; D007986:Luteinizing Hormone; D013006:Growth Hormone; D003847:Deoxyglucose; D005947:Glucose